Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.

Richter J, Lee HC, Jagannath S, Zonder JA, Hoffman JE, Zhou ZY, Garcia-Horton V, Fillbrunn M, Wang H, Mattera M, Inocencio TJ, Xu Y, Harnett J, Roccia T, Kroog GS, Rodriguez Lorenc K, Knorr K, Ma Q, Bumma N

Open source

DOI: 10.1080/10428194.2026.2688561
Published: 2026 Aug
Container: Leukemia & lymphoma
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/10428194.2026.2688561,
  title = {Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.},
  author = {Richter J and Lee HC and Jagannath S and Zonder JA and Hoffman JE and Zhou ZY and Garcia-Horton V and Fillbrunn M and Wang H and Mattera M and Inocencio TJ and Xu Y and Harnett J and Roccia T and Kroog GS and Rodriguez Lorenc K and Knorr K and Ma Q and Bumma N},
  year = {2026},
  journal = {Leukemia \& lymphoma},
  doi = {10.1080/10428194.2026.2688561},
  url = {https://doi.org/10.1080/10428194.2026.2688561}
}

RIS

TY  - JOUR
TI  - Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.
AU  - Richter J
AU  - Lee HC
AU  - Jagannath S
AU  - Zonder JA
AU  - Hoffman JE
AU  - Zhou ZY
AU  - Garcia-Horton V
AU  - Fillbrunn M
AU  - Wang H
AU  - Mattera M
AU  - Inocencio TJ
AU  - Xu Y
AU  - Harnett J
AU  - Roccia T
AU  - Kroog GS
AU  - Rodriguez Lorenc K
AU  - Knorr K
AU  - Ma Q
AU  - Bumma N
PY  - 2026
JO  - Leukemia & lymphoma
DO  - 10.1080/10428194.2026.2688561
UR  - https://doi.org/10.1080/10428194.2026.2688561
ER  -

APA

J, R., HC, L., S, J., JA, Z., JE, H., ZY, Z., V, G., M, F., H, W., M, M., TJ, I., Y, X., J, H., T, R., GS, K., K, R. L., K, K., Q, M., & N, B. (2026). Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.. Leukemia & lymphoma. https://doi.org/10.1080/10428194.2026.2688561

Source records

pubmed · retrieved 2026-09-25T21:26:50.453Z